NAPPEDIII: Norwegian Adenomyosis Study III: Peristalsis

Sponsor
Oslo University Hospital (Other)
Overall Status
Terminated
CT.gov ID
NCT02197936
Collaborator
University of Oslo (Other), Departement of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel (Other), Helse Sor-Ost (Other)
3
1
54
0.1

Study Details

Study Description

Brief Summary

Spontaneous contractions (peristalsis) of the non-pregnant uterus is widely investigated and the role of correct peristalsis is most important for correct sperm transport towards the fallopian tubes and implantation of the embryo, thus obtaining pregnancy. At the same time, an impaired uterine peristalsis is discussed to be the reason for lower pregnancy rates and may also account for heavy menstrual bleedings and menstrual pain.

In this study, the uterine peristalsis of women with adenomyosis will be investigated. This condition is associated to heavy menstrual bleeding, menstrual pain and infertility.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The peristalsis of the non-pregnant uterus is widely investigated and the role of correct peristalsis seems to be most important for correct sperm transport towards the fallopian tubes and implantation of the embryo. At the same time, an impaired uterine peristalsis is discussed to be the reason for lower pregnancy rates and may account for dysmenorrhea and menorrhagia. The connection of impaired peristalsis and various clinical symptoms has been shown for patients with e.g. leiomyoma and endometriosis, but not for women with adenomyosis, though the concept seems to be widely accepted.

    It has also been repeatedly postulated that impaired peristalsis interferes with implantation of the embryo, yet Martinez-Conejero published a trial that showed a higher incidence of miscarriage, but no effect on embryo implantation in women undergoing oocyte donation. This might either indicate that the postulated effect of peristalsis is wrong or, more likely, since this is a study in an IVF setting, that hormonal treatment with gonadotropin-releasing hormone (GnRH)-agonist could improve implantation.

    It is possible to monitor peristalsis with transvaginal ultrasound and standard patterns of uterine peristalsis are defined by Jiland already in 1996.

    Findings resulting from the investigations in this study may help to determine the role and extent of impaired peristalsis in women with adenomyosis and possibly give new clues on potential treatments, as well as fill a gap in today's knowledge.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    3 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part III
    Study Start Date :
    Jul 1, 2014
    Actual Primary Completion Date :
    Jan 1, 2019
    Actual Study Completion Date :
    Jan 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Peristalsis adenomyosis

    with adenomyosis

    Peristalsis control

    No adenomyosis

    Outcome Measures

    Primary Outcome Measures

    1. Frequency of peristaltic waves in Hz [five minutes]

      Frequencies of peristalsis in patients with and without adenomyosis will be compared.

    2. Altitude of peristaltic waves in mm [five minutes]

      The altitude of the peristaltic waves in patients with and without adenomyosis will so be compared.

    Secondary Outcome Measures

    1. direction of uterine peristalsis: antegrade, retrograde [5 minutes, at time of ovulation]

      Dynamic motility characterization of the uterine peristalsis in women with adenomyosis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Premenopausal women aged 20-45 years having been diagnosed with adenomyosis earlier and have no other pathology of the uterus, regardless of clinical symptoms.
    Exclusion Criteria:
    • Postmenopausal women,

    • Pregnant women,

    • Gynaecological cancer,

    • GnRH analog therapy or systemic hormone therapy in the last three months prior to hysterectomy,

    • Endometriosis,

    • Uterine fibroids

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Gynecology, Oslo University Hospital Ullevål and Rikshospital Oslo Norway 0382

    Sponsors and Collaborators

    • Oslo University Hospital
    • University of Oslo
    • Departement of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel
    • Helse Sor-Ost

    Investigators

    • Principal Investigator: Tina Tellum, MD, Oslo University Hospital, Ullevål
    • Study Chair: Marit Lieng, PhD, MD, Oslo University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tina Tellum, Medical Doctor, Oslo University Hospital
    ClinicalTrials.gov Identifier:
    NCT02197936
    Other Study ID Numbers:
    • 2014/637c
    First Posted:
    Jul 23, 2014
    Last Update Posted:
    Mar 5, 2021
    Last Verified:
    Mar 1, 2021
    Keywords provided by Tina Tellum, Medical Doctor, Oslo University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 5, 2021